Renal denervation stutters with shock Medtronic trial failure

Could the “next big thing” in medtech already be set for the scrap heap? Medtronic has just reported that the US pivotal trial of its Symplicity renal denervation device has not met its primary efficacy endpoint, scuppering its chances of FDA approval and sending the firm’s stock down 5% in morning trading.